NEWS

Triveni Bio Doses First Patient in Global Phase 2 Proof-of-Concept Study of TRIV-573	10.13.26
Triveni Bio Raises $65 Million Series C Financing to Drive Next-Stage Company Growth	06.17.26
Triveni Bio Doses First Healthy Volunteers with TRIV-573 Targeting KLK5/7 and IL-13 in Phase 1 Trial	05.18.26
Ovation and PrecisionLife Identify First Potential Genetic Biomarkers to Predict GLP-1 Efficacy Response	02.25.26
Ankyra Therapeutics Presents First Preclinical Data on ANK-203	02.18.26
Compass Therapeutics Announces Key Leadership Appointments	01.05.26

Page 1 of 1